---
kind: "section"
citation: "37 C.F.R. § 1.823"
title: "37"
number: "1.823"
heading: "Requirements for content of a “Sequence Listing” part of the specification."
url: "https://uscodex.org/cfr/37/1.823"
---

# §1.823. Requirements for content of a “Sequence Listing” part of the specification.

- (a) The “Sequence Listing” must comply with the following:
  - (1) The order and presentation of the items of information in the “Sequence Listing” shall conform to the arrangement in appendix G to this subpart. The submission of those items of information designated with an “M” is mandatory. The submission of those items of information designated with an “O” is optional.
  - (2) Each item of information shall begin on a new line, with the numeric identifier enclosed in angle brackets, as shown in appendix G to this subpart.
  - (3) Set forth numeric identifiers <110> through <170> at the beginning of the “Sequence Listing.”
  - (4) Include each disclosed nucleotide and/or amino acid sequence, as defined in [§ 1.821(a)](/cfr/37/1.821.md?p=a).
  - (5) Assign a separate sequence identifier to each sequence, beginning with 1 and increasing sequentially by integers, and include the sequence identifier in numeric identifier <210>.
  - (6) **Use the code “000” in place of the sequence where no sequence is present for a sequence identifier.**
  - (7) Include the total number of SEQ ID NOs in numeric identifier <160>, as defined in appendix G to this subpart, whether followed by a sequence or by the code “000.”
  - (8) **Must not contain more than 74 characters per line.**
- (b)
  - (1) Unless [paragraph (b)(2)](#b-2) of this section applies, if the “Sequence Listing” required by [§ 1.821(c)](/cfr/37/1.821.md?p=c) is submitted as an ASCII plain text file via the USPTO patent electronic filing system or on a read-only optical disc, in compliance with [§ 1.52(e)](/cfr/37/1.52.md?p=e), then the specification must contain a statement in a separate paragraph (see [§ 1.77(b)(5)](/cfr/37/1.77.md?p=b-5)) that incorporates by reference the material in the ASCII plain text file identifying:
    - (i) The name of the file;
    - (ii) The date of creation; and
    - (iii) **The size of the file in bytes.**
  - (2) If the “Sequence Listing” required by [§ 1.821(c)](/cfr/37/1.821.md?p=c) is submitted as an ASCII plain text file via the USPTO patent electronic filing system or on a read-only optical disc, in compliance with [§ 1.52(e)](/cfr/37/1.52.md?p=e) for an international application during the international stage, then incorporation by reference of the material in the ASCII plain text file is not required.
  - (3) A “Sequence Listing” required by [§ 1.821(c)](/cfr/37/1.821.md?p=c) that is submitted as a PDF file ([§ 1.821(c)(2)](/cfr/37/1.821.md?p=c-2)) via the USPTO patent electronic filing system or on physical sheets of paper ([§ 1.821(c)(3)](/cfr/37/1.821.md?p=c-3)), setting forth the nucleotide and/or amino acid sequence and associated information in accordance with [paragraph (a)](#a) of this section:
    - (i) Must begin on a new page;
    - (ii) Must be titled “Sequence Listing”;
    - (iii) Must not include material other than the “Sequence Listing” itself;
    - (iv) Must have sheets containing no more than 66 lines, with each line containing no more than 74 characters;
    - (v) Should have sheets numbered independently of the numbering of the remainder of the application; and
    - (vi) **Should use a fixed-width font exclusively throughout.**

## Notes

### Amendments

[86 FR 57050, Oct. 14, 2021]

### Source

Source: Sections 1.821 through 1.825 appear at 55 FR 18245, May 1, 1990, unless otherwise noted.

### Authority

Authority: 35 U.S.C. 2(b)(2), unless otherwise noted.

### Source

Source: 24 FR 10332, Dec. 22, 1959, unless otherwise noted.

### Amendments

[86 FR 57050, Oct. 14, 2021]